<DOC>
	<DOCNO>NCT02942758</DOCNO>
	<brief_summary>Diagnosis : Acute myeloid leukemia refractory intensive induction chemotherapy ; Age ≥ 60 year , upper age limit ; Study drug : low-dose azacitidine , pioglitazone , ATRA ; Safety Run-In Phase ; randomize Phase II , open-label - Safety Run-In Phase : Based 3 + 3 modified design , tolerable dose ATRA randomize phase II define . - Phase II : Experimental Arm : low-dose azacitidine , pioglitazone , ATRA ; Standard Arm : standard-dose azacitidine ; arm patient receive cycle ( limit number give ) long clinically appropriate</brief_summary>
	<brief_title>Low-dose AZA , Pioglitazone , ATRA Versus Standard-dose AZA Patients &gt; =60 Years With Refractory AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>1 . Patients confirm diagnosis acute myeloid leukemia ( AML ) refractory* induction therapy eligible intensive induction therapy base document medical reason ( e.g . disease characteristic patient characteristic ) , 2 . Patients confirm diagnosis acute myeloid leukemia ( AML ) refractory* induction therapy immediate candidate allogeneic HSCT ( bridge transplant allow ) *refractory induction therapy define CR , CRi PR ( accord standard criterion , see Section 11.2.3 ) least one intensive induction therapy include least 5 day cytarabine 100200 mg/m² continuously equivalent regimen cytarabine total dose less 500 mg/m² per cycle least 2 day anthracycline ( e.g . daunorubicin , idarubicin ) . 3 . Age ≥ 60 ; upper age limit 4 . ECOG performance status ≤ 2 screen 5 . To control hyperleukocytosis extramedullary involvement , medication hydroxyurea allow 24h start study treatment . In case hyperleukocytosis hydroxyurea give start study treatment delay leukocyte count &lt; 20 x 10^9/L . 6 . Female subject childbearing potential* may participate , provide meet following condition : Have negative pregnancy test ( serum urine sensitivity least 25 mIU/mL ; local laboratory ) within 72 hour prior start study therapy . They must agree ongoing pregnancy test course study , end study therapy . This apply even subject practice true abstinence** heterosexual contact . Agree practice true abstinence** heterosexual contact ( must review monthly basis ) agree use , able comply two effective method contraception ( e.g. , oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) without interruption study therapy ( include dose interruption ) , 3 month discontinuation study drug . A female subject childbearing potential ( FCBP ) female : 1 ) achieve menarche point 2 ) undergone hysterectomy bilateral oophorectomy 3 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( ie , menses time precede 24 consecutive month ) . True abstinence acceptable line prefer usual lifestyle subject . Periodic abstinence ( eg , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . 7 . Male patient female partner childbearing potential must agree abstain sexual intercourse use least two effective contraceptive method ( e.g. , synthetic condom spermicide , etc ) screen throughout course study avoid father child course study 3 month follow last study treatment . 8 . Signed write informed consent . 1 . Known suspected hypersensitivity study drug and/or excipients 2 . Patients acute promyelocytic leukemia exhibiting ( 15 ; 17 ) ( q22 ; q12 ) ; PMLRARA , variant translocation 3 . Acute myeloid leukemia ( AML ) isocitratdehydrogenase ( IDH ) 1 2 mutation result available central AMLSG reference laboratory 4 . ECOG performance status &gt; 2 5 . Inadequate cardiac , hepatic and/or renal function Screening Visit define : 1. heart failure NYHA IIIV 2. unstable angina pectoris 3. total bilirubin , ALT , AST &gt; 2.5 x upper normal serum level 4 . Creatinine &gt; 1.5 x upper normal serum level 6 . Active central nervous system involvement 7 . Uncontrolled infection 8 . Uncontrolled diabetes mellitus 9 . Patients `` currently active '' second malignancy require active therapy nonmelanoma skin cancer ( except hormonal/antihormonal treatment , e.g . prostate breast cancer ) 10 . Patients `` currently active '' bladder cancer bladder cancer history , patient risk factor bladder cancer ( e.g . exposure aromatic amine heavy tobacco smoker ) , macrohematuria unknown origin 11 . Severe neurological psychiatric disorder interfere ability give informed consent 12 . Known suspect active alcohol drug abuse 13 . Known positive HIV , active HBV HCV infection 14 . No consent registration , storage process individual disease characteristic course well information family physician and/or physician involve treatment patient study participation . 15 . Treatment clinical study drug within 14 day first administration investigational drug time study 16 . Breast feed woman woman positive pregnancy test Screening Visit 17 . Male patient female partner childbearing potential willing abstain sexual intercourse use least two effective contraceptive method ( e.g. , synthetic condom spermicide , etc ) screen throughout course study 3 month follow last study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>